Related Experiment Videos
Gene delivery to human B-precursor acute lymphoblastic leukemia cells
L Mascarenhas1, R Stripecke, S S Case
1Divisions of Research Immunology/Bone Marrow Transplantation and Hematology/ Oncology, Department of Pediatrics, University of Southern California School of Medicine, Childrens Hospital Los Angeles, Los Angeles, CA, USA.
Blood
|November 10, 1998
Summary
Gene delivery into leukemia cells is key for immunotherapy. Lentiviral vectors show over 90% efficiency in gene transfer for B-precursor acute lymphoblastic leukemia (ALL) cells, offering a promising approach for cancer treatment.
Area of Science:
- Oncology
- Gene Therapy
- Immunology
Background:
- Autologous leukemia cells engineered with immune-stimulating molecules can elicit anti-leukemia immune responses.
- Gene delivery is a critical step in developing cellular immunotherapies for leukemia.
Purpose of the Study:
- To investigate efficient gene delivery methods into human B-precursor acute lymphoblastic leukemia (ALL) cells for potential immunotherapy applications.
Main Methods:
- Evaluated gene transfer efficiency using enhanced green fluorescent protein (EGFP) reporter gene via flow cytometry.
- Compared transfection methods including lipofection, electroporation, and polycationic compounds.
- Assessed retroviral vectors (Moloney murine leukemia virus-based) and lentiviral vectors (HIV-1-based) for gene delivery into ALL cell lines and primary cells.
Main Results:
- Liposomal compound Cellfectin achieved significant gene transfer (3.9-12%) in ALL cell lines.
- Retroviral vectors demonstrated varying transduction efficiencies (0.3-87.5%) depending on the method.
- HIV-1-based lentiviral vectors achieved the highest gene transfer efficiency, transducing >90% of Nalm-6 and Reh cells.
- Both retroviral and lentiviral vectors efficiently transduced primary human B-precursor ALL cells.
Conclusions:
- HIV-1-based lentiviral vectors are highly efficient for gene delivery into B-precursor ALL cells.
- Effective gene delivery into primary ALL cells using these vectors supports their application in immunotherapy development.